%0 Journal Article %T Overview about Candida auris: what's up 12 years after its first description? %+ Hôpital Bretonneau %+ Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR) %+ Université de Lausanne = University of Lausanne (UNIL) %+ Ecologie et biologie des interactions (EBI) %+ Centre de Recherche Saint-Antoine (CRSA) %A Desoubeaux, Guillaume %A Coste, Alix, T %A Imbert, Christine %A Hennequin, Christophe %< avec comité de lecture %@ 1156-5233 %J Journal of Medical Mycology = Journal de Mycologie Médicale %I Elsevier Masson %V 32 %N 2 %P 101248 %8 2022-05 %D 2022 %R 10.1016/j.mycmed.2022.101248 %K Candida auris %K epidemiology %K genetic %K diagnosis %K resistance %K Candida auris %Z Life Sciences [q-bio]/Microbiology and ParasitologyJournal articles %X Candida auris has been described as an emerging yeast species during the last decade. As many as 25% of its strains may naturally exhibit multi-drug resistance to the currently available antifungal drugs. Probably due to its ability to survive more than two weeks on inert surfaces, several large outbreaks have been reported, primarily due to nosocomial transmissions. In addition, due to a rapid worldwide spreading, C. auris is now considered as a major public health threat. This review aims at describing the current knowledge about C. auris, with specific focuses on its global epidemiology, virulence features, most reliable diagnostic approaches, and the current and future therapeutic options. %G English %2 https://hal.sorbonne-universite.fr/hal-03554923/document %2 https://hal.sorbonne-universite.fr/hal-03554923/file/Desoubeaux%20et%20al.%20-%202022%20-%20Overview%20about%20Candida%20auris%20What%27s%20up%2012%20years%20a.pdf %L hal-03554923 %U https://hal.sorbonne-universite.fr/hal-03554923 %~ INSERM %~ UNIV-TOURS %~ CNRS %~ UNIV-POITIERS %~ APHP %~ U938 %~ SORBONNE-UNIVERSITE %~ SORBONNE-UNIV %~ SU-MEDECINE %~ SU-TI %~ EBI %~ ALLIANCE-SU %~ CEPR %~ TEST3-HALCNRS